DUBLIN, April 27,
2022 /PRNewswire/ -- Perrigo Company plc (NYSE:
PRGO), a leading provider of Consumer Self-Care Products,
today announced that it will release its first quarter 2022
financial results on Wednesday, May 11,
2022. The Company will also host a conference call beginning
at 8:30 A.M. (EDT).
The conference call will be available live via webcast to
interested parties in the investor relations section of the Perrigo
website at http://perrigo.investorroom.com/events-webcasts or by
phone at 888-317-6003, International 412-317-6061, and reference ID
# 7280612. A taped replay of the call will be available beginning
at approximately 12:00 P.M. (EDT)
Wednesday, March 11, until midnight Wednesday, May 18, 2022. To listen to the replay,
dial 877-344-7529, International 412-317-0088, and use access code
8916166.
About Perrigo
Perrigo Company plc (NYSE: PRGO) is a leading provider of
Consumer Self-Care Products and over-the-counter (OTC)
health and wellness solutions that enhance individual well-being by
empowering consumers to proactively prevent or treat conditions
that can be self-managed. Led by its consumer self-care strategy,
Perrigo is the largest store brand OTC player in the U.S. in the
categories in which it competes through more than 9,000 SKUs under
customer 'own brand' labels. Additionally, Perrigo is a Top 10 OTC
company by revenue in Europe,
where it markets more than 200 branded OTC products throughout 28
countries. Visit Perrigo online at www.perrigo.com.
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"forecast," "plan," "anticipate," "intend," "believe," "estimate,"
"predict," "potential" or the negative of those terms or other
comparable terminology. The Company has based these forward-looking
statements on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including: the effect of the coronavirus
(COVID-19) pandemic and its variants and the associated supply
chain impacts on the Company's business; general economic, credit,
and market conditions; the impact of the war in Ukraine, including the effects of economic and
political sanctions imposed by the United
States, European Union, and other countries related thereto,
and/or the outbreak or escalation of conflict in other regions
where we do business; future impairment charges; customer
acceptance of new products; competition from other industry
participants, some of whom have greater marketing resources or
larger market shares in certain product categories than the Company
does; pricing pressures from customers and consumers; resolution of
uncertain tax positions, including the Company's appeal of the
draft and final Notices of Proposed Assessment ("NOPAs") issued by
the U.S. Internal Revenue Service and the impact that an adverse
result in any such proceedings would have on operating results,
cash flows, and liquidity; pending and potential third-party claims
and litigation, including litigation relating to the Company's
restatement of previously-filed financial information and
litigation relating to uncertain tax positions, including the
NOPAs; potential impacts of ongoing or future government
investigations and regulatory initiatives; potential costs and
reputational impact of product recalls or sales halts; the impact
of tax reform legislation and healthcare policy; the timing, amount
and cost of any share repurchases; fluctuations in currency
exchange rates and interest rates; the Company's ability to achieve
the benefits expected from the sale of its Rx business and the risk
that potential costs or liabilities incurred or retained in
connection with that transaction may exceed the Company's estimates
or adversely affect the Company's business or operations; the
consummation and success of the proposed acquisition of HRA Pharma
and the ability to achieve the expected benefits thereof, including
the risk that the parties fail to obtain the required regulatory
approvals or to fulfill the other conditions to closing on the
expected timeframe or at all, the occurrence of any other event,
change or circumstance that could delay the transaction or result
in the termination of the securities sale agreement or the risks
that the Company's synergy estimates are inaccurate or that the
Company faces higher than anticipated integration or other costs in
connection with the proposed acquisition; the consummation and
success of other announced and unannounced acquisitions or
dispositions, and the Company's ability to realize the desired
benefits thereof; and the Company's ability to execute and achieve
the desired benefits of announced cost-reduction efforts and
strategic and other initiatives. An adverse result with respect to
the Company's appeal of any material outstanding tax assessments or
pending litigation, including securities or drug pricing matters,
could ultimately require the use of corporate assets to pay such
assessments, damages from third-party claims, and related interest
and/or penalties, and any such use of corporate assets would limit
the assets available for other corporate purposes. These and
other important factors, including those discussed under "Risk
Factors" in the Company's Form 10-K for the year ended December 31, 2021, as well as the Company's
subsequent filings with the United States Securities and Exchange
Commission, may cause actual results, performance or achievements
to differ materially from those expressed or implied by these
forward-looking statements. The forward-looking statements in this
press release are made only as of the date hereof, and unless
otherwise required by applicable securities laws, the Company
disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/perrigo-to-release-first-quarter-2022-financial-results-on-may-11-2022-301534250.html
SOURCE Perrigo Company plc